Sign In
Buy NVRO
$5.84
+0 (+0%)
At Close: Jul 01, 2025
Binge Watching Dopesick? Here Are 3 Stocks That Involve an Opioid-Free Recovery
07:10am, Wednesday, 03'rd Nov 2021
Check out these companies utilizing non-pharmaceutical means to optimize America's health.
Nevro to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
06:00am, Monday, 25'th Oct 2021
REDWOOD CITY, Calif., Oct. 25, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain
Nevro to Report Third Quarter 2021 Financial Results
06:00am, Monday, 11'th Oct 2021
REDWOOD CITY, Calif., Oct. 11, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pai
Nevro Announces Director Appointment
04:05pm, Tuesday, 31'st Aug 2021
REDWOOD CITY, Calif., Aug. 31, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, tod
Nevro to Present at Baird 2021 Global Healthcare Conference
06:00am, Thursday, 26'th Aug 2021
REDWOOD CITY, Calif., Aug. 26, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain,
Nevro to Present at Morgan Stanley 19th Annual Global Healthcare Conference
06:00am, Wednesday, 25'th Aug 2021
REDWOOD CITY, Calif., Aug. 25, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain
Nevro to Present at Wells Fargo Virtual Healthcare Conference
06:00am, Monday, 23'rd Aug 2021
REDWOOD CITY, Calif., Aug. 23, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain,
Why Nevro Is Falling So Hard Today
04:14pm, Thursday, 05'th Aug 2021
A narrower-than-expected loss was about the only bright spot in the company's second-quarter results.
Nevro Stock Tanks After Q2 Earnings Miss, Analysts Move To Sidelines
11:35am, Thursday, 05'th Aug 2021
Nevro Corp (NYSE: NVRO) posted second-quarter revenue of $102.3 million, +81% Y/Y, missing the consensus of $107.7 million. Total U.S. permanent implant procedures increased 60%, while trial procedu
Nevro's (NVRO) CEO Keith Grossman on Q2 2021 Results - Earnings Call Transcript
03:15am, Thursday, 05'th Aug 2021
Nevro's (NVRO) CEO Keith Grossman on Q2 2021 Results - Earnings Call Transcript
Nevro's (NVRO) Senza System Approved by FDA for PDN Treatment
12:23pm, Wednesday, 21'st Jul 2021
Nevro's (NVRO) 10 kHz SCS treatment, which has received the FDA nod for treating patients with PDN, is expected to provide sustained pain relief as well as improve health-related quality of life.
Nevro (NVRO) Reports Impressive Preliminary Q2 Revenues
10:50am, Wednesday, 21'st Jul 2021
Improvement in Nevro's (NVRO) second-quarter revenues is likely to have resulted from a solid product portfolio.
FDA Approves Nevro's Spinal Cord Stimulation For Diabetic Neuropathy Associated Chronic Pain
01:12pm, Monday, 19'th Jul 2021
The FDA has approved Nevro Corp's (NYSE:NVRO) Senza system for treating chronic pain associated with painful diabetic neuropathy (PDN). The approval is specific to Nevro's 10 kHz stimulation.
REDWOOD CITY, Calif., July 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain
Anthem, Deutsche Bank, Nio, Synchrony Financial and More Friday Afternoon Analyst Calls
12:16pm, Friday, 09'th Jul 2021
With the trading day more than halfway over, the broad markets were booming into the weekend.
